Home › NDC Lookup › RxCUI directory › RxCUI 199249

Ritonavir 80 MG/ML Oral Solution — RxCUI 199249

RxNorm drug concept · Semantic clinical drug
RxCUI 199249 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI199249
Official nameRitonavir 80 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asritonavir 80 MG per 1 ML Oral Solution; ritonavir 80 MG in 1 mL Oral Solution
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)2,121 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ritonavir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ritonavir blocks an enzyme called protease that HIV needs to replicate. Without it, the virus can't make mature copies of itself. But ritonavir on its own isn't enough to fully con...
  • What exactly does ritonavir do, and why do I have to take it with other HIV medicines?
  • You're right — stomach side effects like diarrhea, nausea, vomiting, and abdominal pain are very common, especially when you first start. The good news is these often improve after...
  • I've heard ritonavir causes a lot of stomach problems. What should I expect?
📖 Read our full Ritonavir guide →

🕸️ Concept Web — How Ritonavir 80 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ritonavir 80 MG/ML Oral Solution RxCUI 199249

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ritonavir 85762
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ritonavir Oral Solution 373796
    • Ritonavir Oral Liquid Product 1165485
    • Ritonavir Oral Product 1165486
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • Oral Product 1151131
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Ritonavir 80 MG/ML 316647

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ritonavir 80 MG/ML SCDC · 316647
  • Ritonavir Oral Solution SCDF · 373796
  • Ritonavir Oral Liquid Product SCDG · 1165485
  • Ritonavir Oral Product SCDG · 1165486

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 199249 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-2340-30 30 TABLET, FILM COATED in 1 BOTTLE (0074-2340-30) Norvir AbbVie Inc. 2022-08-16
00074-3399-30 30 PACKET in 1 CARTON (0074-3399-30) / 1 POWDER in 1 PACKET Norvir AbbVie Inc. 2017-06-07
Observed labelers: AbbVie Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.